Newsletter
Episode 13 afterward: The biopharma glass is definitively more than half-full

Definitively Speaking

Episode 13 afterward: The biopharma glass is definitively more than half-full

September 8, 2022

Episode 13 afterward: The biopharma glass is definitively more than half-full

Justin, Todd, and special guest Robert Groebel, VP of global life science strategy at Definitive Healthcare, expand on last week’s chat with Pam Randhawa from Empiriko and unpack the challenges, benefits, and opportunities of collaboration in the biopharma market.

How can big pharma, small pharma, academia, and the government all work together? Robert and Todd have some big ideas. They look back at their careers to share professional insights and personal perspectives on the biopharma industry’s evolving playbook—and why they’re looking forward with a healthy dose of optimism.

Justin asks Todd and Robert to answer some big questions: What can biopharma orgs do to address healthcare equity? Is there an insurmountable divide between the industry’s profit motive and academia’s educational mission? And what has Robert feeling so optimistic about biopharma’s impact on patients and caregivers?

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Podcast Sponsors and Advertisers

Event and Media Partners

Buffer LinkedIn WhatsApp